| P50 | author | Nezam Afdhal | Q60650815 |
| P2093 | author name string | M G Myriam Hunink | |
| | Elliot B Tapper | |
| | Michelle Lai | |
| | Neil Sengupta | |
| P2860 | cites work | Vibration-controlled transient elastography: a practical approach to the noninvasive assessment of liver fibrosis | Q38366627 |
| | Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold | Q39268069 |
| | Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study | Q41073361 |
| | Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine | Q41155678 |
| | Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography | Q41456415 |
| | Low yield and utilization of confirmatory testing in a cohort of patients with liver disease assessed for alpha-1 antitrypsin deficiency | Q41658735 |
| | Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up | Q42201783 |
| | The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies | Q45209585 |
| | Management of nonalcoholic fatty liver disease: a 60-year-old man with probable nonalcoholic fatty liver disease: weight reduction, liver biopsy, or both? | Q47300087 |
| | Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss | Q47417361 |
| | The overuse of serum ceruloplasmin measurement | Q47760519 |
| | The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. | Q51089882 |
| | Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. | Q51171810 |
| | Trends in outpatient resource utilizations and outcomes for Medicare beneficiaries with nonalcoholic fatty liver disease. | Q51241968 |
| | Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease | Q58622754 |
| | The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease | Q58803093 |
| | Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting | Q61860180 |
| | The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD | Q61989968 |
| | Understanding and Reducing Ceruloplasmin Overuse with a Decision Support Intervention for Liver Disease Evaluation | Q64049155 |
| | Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan® | Q82980218 |
| | Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease | Q87406034 |
| | Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis | Q21144594 |
| | Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis | Q24625697 |
| | Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994 | Q28384968 |
| | The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association | Q29617157 |
| | Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. | Q30366569 |
| | Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis | Q33563333 |
| | Liver biopsy | Q33932981 |
| | Burden of gastrointestinal disease in the United States: 2012 update | Q34293512 |
| | Simple non-invasive biomarkers of advanced fibrosis in the evaluation of non-alcoholic fatty liver disease | Q34447506 |
| | Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis | Q34830398 |
| | Dropping the baton: specialty referrals in the United States | Q35178147 |
| | Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease | Q35893923 |
| | Specialty referral completion among primary care patients: results from the ASPN Referral Study | Q35916931 |
| | Levels of alanine aminotransferase confound use of transient elastography to diagnose fibrosis in patients with chronic hepatitis C virus infection | Q36110037 |
| | Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods. | Q38070696 |
| | Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments | Q38168939 |
| | Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies | Q38207382 |
| | FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice | Q38218609 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | liver disease | Q929737 |
| | metabolic dysfunction–associated steatotic liver disease | Q1546498 |
| | fatty liver disease | Q6058862 |
| P304 | page(s) | e0147237 | |
| P577 | publication date | 2016-02-23 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score | |
| P478 | volume | 11 | |